Mohammad Eldeeb

Board Certified, Fellowship trained, Interventional pain medicine physician with excellent medical and interventional skills, leadership experience and practice management experience seeking a position to make a difference in the community by improving patients’ quality of life, functionality and happiness by decreasing their suffering. Compassionate physician with experience offering comprehensive patient care in outpatient settings. Work well with diverse patient populations and foster communication trusting relationships to improve outcomes. Efficiently coordinate with healthcare professionals to advance patient care. Pride myself on being a team player, a people person despite having excellent leadership experience and skills.

• Protocol A0081268: A Study Of Pregabalin In The Treatment Of Subjects With Painful Diabetic Peripheral Neuropathy With Background Treatment Of NSAIDs For Other Pain Conditions.
• Protocol A0081269: A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled Cross-Over Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Painful Diabetic Peripheral Neuropathy And Pain n Walking.
• Protocol: CP505.2001: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Ctp-499 600 Mg Twice-Daily In Type 2 Diabetic Nephropathy Patients Who Are Currently Being Treated With Angiotensin Converting Enzyme Inhibitor (Acei) And/Or Angiotensin Ii Receptor Blocker (Arb) Therapy
• Protocol: NN9068-3851 DUAL III - GLP-1 Switch - The efficacy of insulin Degludec/Liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and Xtherapy
• Protocol: SP304-20212: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
• MK0974-049: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial To Study the Safety and Efficacy of XXXX for Migraine Prophylaxis in Patients With Episodic Migraine.
• MK0974-034: A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Crossover Study to Evaluate the Safety and Efficacy of XXX in the Treatment of Acute Migraine in Patients with Stable Vascular Disease.
• MK0974-065: A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine.
• Protocol: D5612C00001: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXXXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
• Protocol 1314V9231: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy
• Protocol 27018966IBS3001: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
• Protocol MK-3102-026: A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared with the Addition of Sitagliptin in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin | 1/2014 - 11/2016
• Protocol APD356-G000-401: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors | 07/2014 – 08/2018
• Protocol FEB-XR_301: A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout | 07/2014 – 01/2016
• Protocol R475-PN-1227: A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain due to Osteoarthritis of the Knee or Hip | 06/2015 - 9/2016
• Protocol ALD403-CLIN-006: A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraines| 10/2015 – 2/2018
• Protocol BAY94-8894-16244: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event driven phase III study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. | 10/2015 – 01/2017
• Protocol BAY94-8894-17530: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of Finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care | 10/2015 – 04/2021
• Protocol OC-EG-303: An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients with Moderate to Severe Chronic Noncancer Pain | 1/2016 – 09/2017
• Protocol MK-8835-004-01/B1521021: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to assess Cardiovascular Outcomes following treatment with Ertugliflozin (Mk-8835/Pf-04971729) in subjects with Type 2 Diabetes Mellitus and established Vascular Disease, The Vertis Cv Study | 10/2016 – 06/2020
• Protocol ALD403-CLIN-013: An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients with Chronic Migraines | 11/2016 – 05/2019
• Protocol ALDCLIN-403-011: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine | 1/2017 – 5/2018
• Protocol VF00102: A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care in Patients with Chronic Venous Leg Ulcers | 1/2017 – 10/2017
• Protocol EFC14834: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin | 2/2018 – 08/2019
• Protocol RBI.2017.002: A Multi-Center, Double-Blind, Sham-Controlled, Randomized Trial of Dual Field PEMF Therapy [Provant Therapy System] in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy | 4/2018 – 11/2019
• Protocol EFC14838: A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Glimepiride or Placebo Added to Metformin in Patients with Type 2 Diabetes who have Inadequate Glycemic Control with Metformin Monotherapy | 5/2018 – 11/2018
• Protocol INP104-301: Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered using the I123 Precision Olfactory Delivery (POD ) Device [INP104, POD-DHE] in Patients with Migraine Headache Stop 301 Trial (Safety and Tolerability of POD-DHE) | 6/2018 – 06/2020
• Protocol IT001-301: A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract infections in adult women. | 08/2018 – 08/2020
• Protocol SM04690-OA-11: A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects | 05/2019 – 11/2021
• Protocol ALD403-CLIN-015: A Parallel Group Double-Blind Randomized PlaceboControlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine | 11/2019 – 9/2020
• Protocol SM04690-OA-10: A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects | 3/2020 – 11/2021
• Protocol SM04690-OA-15: A Study to Support the Radiographic Eligibility Screening Process of Samumed Studies in Symptomatic Knee Osteoarthritis Subjects | 3/2020 – 11/2021
• SM04690-OA-07: A 48-Week, Placebo-Controlled, Single Blind Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Osteoarthritis of the Knee |11/2020 - 09/2023
• Protocol C4491011: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants with Dyslipidemia | 01/2021 – 02/2022
• Protocol ABP-20001: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (PrabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache | 05/2021 - Ongoing
• Protocol ABP-20002: A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (PrabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache | 3/2022 – Ongoing
• Protocol 20007A (RESOLUTION): Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on Eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache (Phase 4) | 05/2022 – 03/2024
• Protocol SM04690-OA-21: A Phase 3, 16-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg Dose in the Target Knee Joint of Subjects with Moderate to Severe Osteoarthritis Pain of the Knee | 02/2023 - 03/2024

• Pain Medicine fellowship, St. Vincent Hospital, New York, NY and Brookdale University Hospital, Brooklyn, NY, 2005, 2006
• Anesthesiology Residency, Brookdale University Hospital, Brooklyn, NY, 2001, 2005
• Medical Doctor, Cairo University School of Medicine, Cairo, Egypt, 1986, 1992
• IGCSE, London University, 1985, 1986

• Member of ASIPP
• Member of WIP
• Member of IPSIS
• CIR delegate for 2 years
• CIR alternate delegate for 2 years
• President of Student Medical Society (SMS), President of Student Scientific Society (SSS) 1986-1992
• President of Student council, Medical School, Cairo University, 1986-1992

Medical License - Active Unrestricted Florida Medical license